# Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer

> **NCT01658462** · PHASE2 · COMPLETED · sponsor: **Centre Oscar Lambret** · enrollment: 51 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Nintedanib
- **DRUG:** Docetaxel: increase of the dose

## Key facts

- **NCT ID:** NCT01658462
- **Lead sponsor:** Centre Oscar Lambret
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2016-12-31
- **Final completion:** 2017-10-30
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2026-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01658462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01658462, "Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT01658462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*